InvestorsHub Logo
Followers 19
Posts 932
Boards Moderated 0
Alias Born 06/29/2020

Re: Venture_Cap post# 90563

Friday, 07/03/2020 10:13:31 PM

Friday, July 03, 2020 10:13:31 PM

Post# of 232944
Ryoncil trial was related to GVHD study. They think it might be effective for COVID but they have not had trials specifically for COVID that I can see. They are doing like most companies including Cytodyn (from previous trials with HIV) that make them think it might work for COVID. However, Cytodyn has trials going.
http://investorsmedia.mesoblast.com/static-files/c0807204-3d05-4b03-adb9-d05066d8491d From their report: "“Results from these three trials show a consistent pattern of safety and efficacy for RYONCIL (remestemcel-L) in patients with the greatest levels of inflammation and the most severe grades of acute GVHD. These clinical outcomes provide a compelling rationale for use of remestemcel-L in children and adults with other conditions associated with severe inflammation and cytokine release, including acute respiratory distress syndrome (ARDS) and systemic vascular manifestations of COVID-19 infection.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News